Characteristics of anal canal squamous cell carcinoma as an HPV-associated cancer in Japan

• Published in: International journal of clinical oncology Vol. 28; no. 8; pp. 990 - 998
• Main Authors: Yamada, Kazutaka, Shiraishi, Kouya, Takashima, Atsuo, Takayanagi, Daisuke, Saiki, Yasumitsu, Takano, Shota, Tanaka, Masafumi, Fukunaga, Mitsuko, Sugimoto, Kosuke, Iwasaki, Yuki, Nakamura, Yasushi, Kuwahara, Daisaku, Tsuji, Yoriyuki, Takano, Masahiro, Sugihara, Kenichi, Ajioka, Yoichi
• Format: Journal Article
• Language: English
• Published: Singapore Springer Nature Singapore 01.08.2023; Springer Nature B.V
• Subjects: Adenocarcinoma; Adenosquamous; Anal cancer; Anus; Canals (anatomy); Cancer; Cancer Research; Cancer therapies; Colon cancer; Genotypes; Human papillomavirus; Immunization; Invited Review Article; Medical prognosis; Medicine; Medicine & Public Health; Oncology; Patients; Risk factors; Squamous cell carcinoma; Statistical analysis; Surgical Oncology; Japan; Squamous cell carcinoma; Human papillomavirus; Chemoradiotherapy; Anal canal cancer
• ISSN: 1341-9625; 1437-7772
• DOI: 10.1007/s10147-023-02339-5

The definition of the anal canal was revised in the TNM classification (8th edition). The Japanese Society for Cancer of the Colon and Rectum (JSCCR) conducted a retrospective multi-institutional study to clarify the characteristics of anal canal cancer (ACC) in Japan. The diagnoses of 1781 patients treated for ACC were squamous cell carcimoma (SCC; n = 428; 24.0%), adenosquamous cell carcinoma (n = 7; 0.4%), and adenocarcinoma (n = 1260; 70.7%). Anal carcinoma is associated with human papillomavirus (HPV) infection and is risk factor for anal SCC. Among 40 cases analyzed at Takano Hospital and 47 cases analyzed at National Cancer Center Hospital, 34 cases (85.0%) and 40 cases (85.1%), respectively were infected with HPV; HPV-16 was the most common genotype (79.4% and 82.5%). In the JSCCR retrospective multi-institutional study, the prognosis analysis by stage was performed for anal SCC cases (202 cases treated by CRT and 91 cases treated by surgery). The 5-year overall survival (OS) rates by stage did not differ between the two treatment groups to a statistically significant extent. Regarding the results of cancer treatment of patients who underwent HPV infection tests, although the 5-year OS rates by stage did not differ to a statistically significant extent due to the small number of cases, HPV-positive patients had better survival. While an HPV vaccine for anal canal SCC has already been approved internationally, HPV vaccination has already been implemented in Japan as a national immunization program for young women but not for men at present. An HPV vaccination for men is urgently needed.